Cargando…

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma

Background  The concept of combinational analysis between the methylation of O (6) -methylguanine-DNA methyltransferase ( MGMT ) and telomerase reverse transcriptase promoter ( pTERT ) mutation in glioblastoma (GBM) has been reported. The main study objective was to determine the prognosis of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunthanathip, Thara, Sangkhathat, Surasak, Tanvejsilp, Pimwara, Kanjanapradit, Kanet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559075/
https://www.ncbi.nlm.nih.gov/pubmed/34744391
http://dx.doi.org/10.1055/s-0041-1735821
_version_ 1784592685866156032
author Tunthanathip, Thara
Sangkhathat, Surasak
Tanvejsilp, Pimwara
Kanjanapradit, Kanet
author_facet Tunthanathip, Thara
Sangkhathat, Surasak
Tanvejsilp, Pimwara
Kanjanapradit, Kanet
author_sort Tunthanathip, Thara
collection PubMed
description Background  The concept of combinational analysis between the methylation of O (6) -methylguanine-DNA methyltransferase ( MGMT ) and telomerase reverse transcriptase promoter ( pTERT ) mutation in glioblastoma (GBM) has been reported. The main study objective was to determine the prognosis of patients with GBM based on MGMT/pTERT classification, while the secondary objective was to estimate the temozolomide effect on the survival time of GBM with MGMT/pTERT classification. Methods  A total of 50 GBM specimens were collected after tumor resection and were selected for investigating MGMT methylation and pTERT mutation. Clinical imaging and pathological characteristics were retrospectively analyzed. Patients with MGMT/pTERT classification were analyzed using survival analysis to develop the nomogram for forecasting and individual prognosis. Results  All patients underwent resection (total resection: 28%, partial resection: 64%, biopsy: 8%). Thirty-two percent of all cases received adjuvant temozolomide with radiotherapy. Sixty-four percent of the case was found methylated MGMT , and 56% of the present cohort found pTERT mutation. Following combinational analysis of biomarkers, results showed that the GBMs with methylated MGMT and wild-type pTERT had a superior prognosis compared with other subtypes. Using Cox regression analysis with multivariable analysis, the extent of resection, postoperative chemoradiotherapy, MGMT/pTERT classification were associated with a favorable prognosis. Hence, a web-based nomogram was developed for deploying individual prognostication. Conclusions  The interaction of MGMT methylation and pTERT mutation was confirmed for predicting prognosis. The results from the present study could help physicians create treatment strategies for GBM patients in real-world situations.
format Online
Article
Text
id pubmed-8559075
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-85590752021-11-04 Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma Tunthanathip, Thara Sangkhathat, Surasak Tanvejsilp, Pimwara Kanjanapradit, Kanet J Neurosci Rural Pract Background  The concept of combinational analysis between the methylation of O (6) -methylguanine-DNA methyltransferase ( MGMT ) and telomerase reverse transcriptase promoter ( pTERT ) mutation in glioblastoma (GBM) has been reported. The main study objective was to determine the prognosis of patients with GBM based on MGMT/pTERT classification, while the secondary objective was to estimate the temozolomide effect on the survival time of GBM with MGMT/pTERT classification. Methods  A total of 50 GBM specimens were collected after tumor resection and were selected for investigating MGMT methylation and pTERT mutation. Clinical imaging and pathological characteristics were retrospectively analyzed. Patients with MGMT/pTERT classification were analyzed using survival analysis to develop the nomogram for forecasting and individual prognosis. Results  All patients underwent resection (total resection: 28%, partial resection: 64%, biopsy: 8%). Thirty-two percent of all cases received adjuvant temozolomide with radiotherapy. Sixty-four percent of the case was found methylated MGMT , and 56% of the present cohort found pTERT mutation. Following combinational analysis of biomarkers, results showed that the GBMs with methylated MGMT and wild-type pTERT had a superior prognosis compared with other subtypes. Using Cox regression analysis with multivariable analysis, the extent of resection, postoperative chemoradiotherapy, MGMT/pTERT classification were associated with a favorable prognosis. Hence, a web-based nomogram was developed for deploying individual prognostication. Conclusions  The interaction of MGMT methylation and pTERT mutation was confirmed for predicting prognosis. The results from the present study could help physicians create treatment strategies for GBM patients in real-world situations. Thieme Medical and Scientific Publishers Pvt. Ltd. 2021-09-28 /pmc/articles/PMC8559075/ /pubmed/34744391 http://dx.doi.org/10.1055/s-0041-1735821 Text en Association for Helping Neurosurgical Sick People. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Tunthanathip, Thara
Sangkhathat, Surasak
Tanvejsilp, Pimwara
Kanjanapradit, Kanet
Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
title Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
title_full Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
title_fullStr Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
title_full_unstemmed Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
title_short Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
title_sort prognostic impact of the combination of mgmt methylation and tert promoter mutation in glioblastoma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559075/
https://www.ncbi.nlm.nih.gov/pubmed/34744391
http://dx.doi.org/10.1055/s-0041-1735821
work_keys_str_mv AT tunthanathipthara prognosticimpactofthecombinationofmgmtmethylationandtertpromotermutationinglioblastoma
AT sangkhathatsurasak prognosticimpactofthecombinationofmgmtmethylationandtertpromotermutationinglioblastoma
AT tanvejsilppimwara prognosticimpactofthecombinationofmgmtmethylationandtertpromotermutationinglioblastoma
AT kanjanapraditkanet prognosticimpactofthecombinationofmgmtmethylationandtertpromotermutationinglioblastoma